Company newsCompany release

Viking Therapeutics VKTX

Viking Therapeutics shares VK2735 obesity trial analysis at ObesityWeek 2026

In an exploratory analysis of its Phase 2 VENTURE trial, 74% of participants on weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, versus 15% on placebo.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Viking Therapeutics said on November 15, 2026 that new clinical data from its VK2735 obesity program were highlighted in two poster presentations at The Obesity Society's Annual Meeting, ObesityWeek, which runs from November 14 to 17, 2026, in Washington, D.C.

The company presented results from an exploratory analysis of its Phase 2 VENTURE trial, in which participants received VK2735 as a weekly subcutaneous injection. The analysis covers changes in obesity severity and cardiometabolic measures after 13 weeks. It found that 74% of participants receiving weekly subcutaneous VK2735 improved by at least one body mass index category, compared with 15% of placebo participants. None of the VK2735-treated participants had an increase in BMI category.

Among VK2735-treated participants, those who improved by at least one BMI category showed greater reductions in waist circumference, fasting insulin and glucose, blood pressure, total cholesterol, triglycerides and LDL cholesterol than those whose BMI category did not change.

Brian Lian, Ph.D., chief executive officer of Viking Therapeutics, said the analysis supports the company's belief that weight loss from VK2735 treatment may improve overall cardiometabolic health.

A second poster presented baseline characteristics of participants in the ongoing Phase 3 VANQUISH-2 study, which evaluates subcutaneous VK2735 in adults with overweight or obesity and type 2 diabetes. Jamy Ard, MD, presented it. Viking Therapeutics said the VANQUISH studies are expected to be completed in 2027.

Key facts

Participants on weekly subcutaneous VK2735 with at least one BMI category improvement
74%
Placebo participants with at least one BMI category improvement
15%
VK2735-treated participants with an increase in BMI category
None
ObesityWeek dates
November 14 to 17, 2026
VANQUISH studies expected to be completed
2027

All VKTX news

Source: The company's release on PR Newswire, November 15, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

Viking Therapeutics first, then the newest
  1. Rocket Lab reaches 100 Electron launches

    RKLB · Rocket Lab · Company release · Nov 14, 2026

All company news